Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1

Lisha Gou a,b, Huawei Zou a,b, and Beibei Li a,b

a Department of Endocrine, Zhoukou Central Hospital, Zhoukou, Henan, 466000, China; b Department of Thyroid Surgery, Zhoukou Central Hospital, Zhoukou, Henan, China

ABSTRACT

Long noncoding RNAs (lncRNAs) have been reported to play essential roles in progression of thyroid carcinoma. However, the roles of lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in anaplastic thyroid carcinoma (ATC) process and its mechanism remain not been fully established. In this study, we focused on the effect of MALAT1 on cell proliferation, apoptosis, migration, invasion, and autophagy formation in ATC and explored the interaction between miR-200a-3p and MALAT1 or FOXA1. Moreover, murine xenograft model was established to investigate the roles and mechanism of MALAT1 in ATC progression in vivo. Results showed that MALAT1 expression was enhanced and miR-200a-3p was reduced in ATC tissues and cells. Knockdown of MALAT1 or over-expression of miR-200a-3p inhibited cell proliferation, migration and invasion but increased apoptosis and autophagy formation in ATC cells. Moreover, miR-200a-3p was directly bound to MALAT1 and its inhibition reversed the inhibitory effect of MALAT1 knockdown on progression of ATC. In addition, FOXA1 was indicated as a target of miR-200a-3p and its restoration attenuated the anti-cancer role of miR-200a-3p in ATC cells. Furthermore, MALAT1 functioned as a competing endogenous RNA (ceRNA) via sponging miR-200a-3p to derepress FOXA1 expression. Besides, interference of MALAT1 decreased tumor growth by upregulating miR-200a-3p and downregulating FOXA1. Collectively, MALAT1 knockdown suppressed ATC progression by regulating miR-200a-3p/FOXA1, providing a novel avenue for treatment of ATC.

Introduction

Thyroid cancer is the most common endocrine malignancy with rising incidence worldwide. Thyroid cancer manifests as various subtypes, such as papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). Among these subtypes, ATC is the deadliest thyroid cancer with survival rate of six months. Many treatments have been used to ATC therapy, while the effective and specific strategies are lacked. Hence, it calls for further efforts to explore novel biomarker for diagnosis and therapeutics of ATC.

Long noncoding RNAs (lncRNAs) have been reported to play essential roles in tumorigenesis in various cancers, including thyroid cancer. For example, lncRNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) has been indicated as a tumor suppressor to inhibit drug resistance of ATC by regulating signal transducers and activators of the transcription 3 (STAT3). LncRNA urothelial carcinoma associated 1 (UCA1) has been suggested to regulate ATC development through regulating proliferation and migration via microRNA-135a (miR-135a). LncRNA linc00312 inhibits cell proliferation, migration and invasion by down-regulating miR-197-3p in ATC. As for lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), it has been reported to be highly associated with human cancers and target anti-cancer approaches. Moreover, MALAT1 has been reported to function as onco-gene or tumor suppressor in different subtypes of thyroid cancer. Besides, MALAT1 is suggested to be highly expressed in thyroid cancer and associate with tumor malignancy. However, the exact roles of MALAT1 in progression of ATC and its mechanism remain poorly understood.

Competing endogenous RNA (ceRNA) networks hypothesis has been proposed in various cancers, which suggests that lncRNAs can act as miRNA decoys to regulate related gene expression. miR-200a-3p has been suggested to be dysregulated in thyroid cancer. Moreover, emerging evidence revealed that lncRNA small nuclear RNA host gene 15 (SNHG15) regulates progression of thyroid cancer by sponging miR-200a-3p. However, there is no evidence in support of the roles of miR-200a-3p in ATC and the interaction between MALAT1 and miR-200a-3p. Forkhead box A1 (FOXA1), a member of FOX family, has been suggested to be expressed in thyroid tumors. In addition, available evidence has indicated FOXA1 as a potential onco-gene in ATC to regulate cell proliferation and cell cycle. Bioinformatics analysis exhibits the putative binding sites between miR-200a-3p and MALAT1 or FOXA1. Hence, we hypothesized that MALAT1 might regulate progression of ATC by acting as...
a ceRNA for miR-200a-3p to modulate FOXA1 expression. In this study, we measured the expression of MALAT1 in ATC tissues and cells. Moreover, we investigated the effect of MALAT1 on cell proliferation, apoptosis, migration, invasion, and autophagy formation and explored the ceRNA regulatory network of MALAT1/miR-200a-3p/FOXA1.

Materials and methods

Patients specimens

A total of 30 patients with ATC without chemotherapy, radiotherapy, or others’ therapy were enrolled from Zhoukou Central Hospital in this study. The ATC tissues and adjacent normal samples were collected, immediately frozen in liquid nitrogen and then stored at −80°C until used. Written informed consent was obtained from all participants and this study instruction was approved by the Research Ethics Committee of Zhoukou Central Hospital. The low MALAT1 expression group and high expression group were classified according to the median value of MALAT1 expression level in ATC patients. The survival rate was analyzed in patients after the follow-up.

Cell culture and transfection

Human ATC cell lines (SW1736 and 8505C) and human thyroid follicular epithelial cell line Nthy-ori 3-1 were purchased from American Tissue Culture Collection (ATCC, Manassas, VA, USA). All cells were cultured in DMEM (11965092, Thermo Fisher, Wilmington, DE, USA) supplemented with 10% FBS (10100154, Thermo Fisher), 100 U/ml penicillin and 100 mg/ml streptomycin (15140122, Thermo Fisher, Wilmington, DE, USA) supplemented with 10% FBS (10100154, Thermo Fisher) and 100 U/ml penicillin and 100 mg/ml streptomycin (15140122, Thermo Fisher) at 37°C in an incubator with 5% CO₂.

Small interfering RNA (siRNA) against MALAT1 (siMALAT1), siRNA scrambled control (Scramble), MALAT1 overexpression vector (MALAT1), FOXA1 overexpression vector (FOXA1), empty vector, miR-200a-3p mimic (miR-200a-3p), negative control (NC), miR-200a-3p inhibitor (anti-miR-200a-3p), and anti-NC were obtained from GenePharma (Shanghai, China). SW1736 and 8505C cells were transfected with 50 nM oligonucleotides or 2 µg of vector by using Lipofectamine 3000 (L3000015, Thermo Fisher) according to the manufacturer’s protocol. Transfection efficiency was investigated by quantitative real-time polymerase chain reaction (qRT-PCR). Further experiments were conducted at 72 h after transfection.

qRT-PCR

Total RNA was isolated from tissues or cells by using Trizol reagent (15596018, Thermo Fisher) following the manufacturer’s instructions. Total RNA was reverse transcribed by using TaqMan Reverse Transcription Kit or TaqMan microRNA Reverse Transcription Kit (N8080234 and 4366596, Thermo Fisher). Subsequently, the synthetic complementary DNA (cDNA) was diluted and used for qRT-PCR using SYBR green detection kit (QPK-201, Toyobo, Tokyo, Japan) on ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) following the amplification instructions. All primers were obtained from Sangon Biotech (Shanghai, China): MALAT1 (Forward, 5’-TGC GAGTGTCTTCGGCTCTTA-3; Reverse, 5’-TATCTGGGGTTTC TCTAAGC-3), FOXA1 (Forward, 5’-GAATATCTCGCCCTAAC GGCT-3; Reverse, 5’-TACACACCTTGTTAAGTCGGCC-3), GAPDH (Forward, 5’-CTGGGCTACACTGAGACC-3; Reverse, 5’-AAAGTGTCGTGGAGGGCAGATG-3), miR-200a-3p (Forward, 5’-CCT CCGCCACAAATTAACACCGC-3; Reverse, 5’-C CGGTCTAAAACACCTGTGG TA-3), U6 (Forward, 5’-ATGG GAACGATACAGAGAAGATT-3; Reverse, 5’-GG AACGCTT CACGAATTG-3). The experiment was conducted three times and the expressions of RNA were evaluated with 2^−ΔΔCt method using U6 small RNA or GAPDH as internal control, respectively.

Cell proliferation

Cell proliferation was analyzed by MTT (3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium 4) (M1020, Solarbio, Beijing, China) according to the manufacturer’s instructions. SW1736 and 8505C cells were inoculated in 96-well plates at a density of 5 × 10⁴ cells per well. Each well was added to 10 μl MTT dye at 24, 48, or 72 h after the transfection. After the incubation for another 4 h, the absorbance at 570 nm was detected by using microplate reader (Bio-Rad, Hercules, CA, USA). Every sample was prepared in triplicate and experiment was repeated three times.

Cell apoptosis

Cell apoptosis was measured by flow cytometry using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (APOAF, Sigma, St. Louis, MO, USA) according to the manufacturer’s protocols. Transfected SW1736 and 8505C cells were collected and incubated with Annexin V-FITC and PI for 20 min in the dark. The apoptotic cells were analyzed by using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Trans-well assay

Migrated and invasive abilities of cells were detected by trans-well assay. For cell migration, SW1736 or 8505C cells (2 × 10⁴ cells/well) in serum-free DMEM medium were placed in the upper chambers (Costar, Corning, NY, USA), and 500 μl DMEM medium containing 10% FBS was added to the lower chambers. After the incubation for 24 h, cells on the top surface were removed with a cotton swab, and migrated cells on the basal side of the membranes were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (C6158, Sigma), followed by counted under a microscope (Olympus, Tokyo, Japan). For cell invasion, Matrigel (354230, BD Biosciences) was used to pre-coat the trans-well chambers and the experiment was performed following the similar approach.

GFP-LC3 puncta fluorescence assay

Cells were transfected with GFP-LC3 (GenePharma) for 24 h according to the manufacturer’s instructions. After the transfection, cells were fixed with 4% formaldehyde and stained
with DAPI (D9542, Sigma), followed by observed using fluorescence microscope (Olympus).

**Western blot**

Collected cells or tissues were lysed in RIPA lysis buffer (89901, Thermo Fisher) containing 1% protease inhibitor (P8340, Sigma) and centrifuged at 12,000 × g for 10 min. Then, the supernatant was collected and quantified via bicinchoninic acid (BCA) protein assay kit (BCA1, Sigma), followed by denatured at 98°C for 10 min. The total proteins were separated by SDS-PAGE gel electrophoresis and then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat milk in Tris-buffer saline containing 0.1% Tween 20 (TBST) for 1 h at room temperature, and then incubated with primary antibodies overnight at 4°C and HRP-conjugated secondary antibodies (ab6721) for 2 h at room temperature. The antibodies against Beclin-1 (ab62557), LC3 (ab51520), FOXA1 (ab151522), or GAPDH (ab181602) were purchased from Abcam (Cambridge, UK). The protein signals were visualized using films via enhanced chemiluminescence (ECL) chromogenic substrate (32209, Thermo Fisher) in the dark.

**Luciferase activity assays**

The putative binding sites of miR-200a-3p and MALAT1 or FOXA1 were predicted by starBase v2.0 or TargetScan software online. The 3′ untranslated regions (3′-UTR) of MALAT1 or FOXA1 containing wild-type (wt) or mutant (mut) binding sites of miR-200a-3p were amplified and cloned into pmirGLO luciferase reporter vector (Promega, Madison, WI, USA) to generate the wt plasmids (MALAT1-wt, FOXA1-wt) or mut plasmids (MALAT1-mut, FOXA1-mut), respectively. The NC, miR-200a-3p, anti-NC or anti-miR-200a-3p was co-transfected with wt or mut luciferase reporter plasmids into 8505C cells according to the manufacturer’s protocols. The luciferase activities were analyzed by using Dual-Luciferase Assay Kit (Promega) after transfection for 48 h, and normalized to the Renilla luciferase activity.

**RNA immunoprecipitation (RIP)**

The relationship between miR-200a-3p and MALAT1 or FOXA1 was measured by using Magna RIP Kit (Millipore) following the manufacturer’s instructions. In brief, 8505C cells were transfected with miR-200a-3p or NC for 48 h. Then, RIP assay was conducted by using magnetic beads (Thermo Fisher) bounded with anti-arginate 2 (anti-Ago2) (ab32381, Abcam) or IgG (AP112, Sigma) antibodies. The RNA in beads complexes was isolated and measured by qRT-PCR.

**RNA pull-down assay**

RNA pull-down analysis was conducted in 8505C cells by using RNA-Protein Pull-Down Kit (T20164, Thermo

---

Figure 1. MALAT1 expression was enhanced in ATC tissues and cells. (A) The level of MALAT1 was measured in ATC tissues and adjacent normal samples by qRT-PCR. *n* = 30. (B) The abundance of MALAT1 was detected in ATC cells and Nthy-ori 3-1 cells by qRT-PCR. (C) The survival rate was analyzed between low and high MALAT1 expression group in ATC patients. *P* < .05.
Fisher). In brief, NC or miR-200a-3p was labeled with biotin and transfected into 8505C cells. The cell lysates were incubated with streptavidin agarose beads (Invitrogen) for 2 h, followed by eluted with biotin elution buffer. The complex was used for measurement of MALAT1 abundance by qRT-PCR.

**Tumor xenograft model**

Lentivirus-mediated shRNA interference targeting MALAT1 (shMALAT1) and Scramble were constructed by GeneCopoeia (Rockville, MD, USA) and then transfected into SW1736 or 8505C cells, respectively. Stably transfected cells (1 × 10^6) were inoculated subcutaneously in BALB/c nude mice (male, 5-week-old, Vital River Laboratory Animal Technology, Beijing, China). Every effort was made to minimize animals (n = 7/group) during the study and performed in accordance with the instructions approved by the committee of Animal Research of Zhoukou Central Hospital. Tumor volume was examined every five days for six times with slide calipers and calculated as 0.5 × length × width × height. At 30 days after cell implantation, mice were sacrificed and tumor specimens were weighed and collected for measurement of miR-200a-3p and FOXA1 abundances.

**Statistical analysis**

The data were expressed as the mean ± standard deviation (S.D.) from three independent experiments. Kaplan–Meier method was used to generate survival curve, and log-rank test was used for statistical analysis. Spearman rank correlation was performed to explore the correlations among miR-200a-3p, MALAT1, and FOXA1. The statistical differences between groups were analyzed by Student’s t test using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). P < .05 was regarded as statistically significant.

**Results**

**MALAT1 expression was increased in ATC tissues and cells**

To explore the potential roles of MALAT1 in ATC, its expression was measured in ATC tissues and cells. Compared with adjacent normal tissues, ATC samples...
Figure 3. Overexpression of miR-200a-3p inhibited progression of ATC cells. The expressions of miR-200-3p were measured in ATC tissues (A) and cells (B) by qRT-PCR. (C) The abundance of miR-200a-3p was detected in SW1736 and 8505C cells transfected with miR-200a-3p or NC by qRT-PCR. Cell proliferation (D), apoptosis (E), migration (F), invasion (G), and autophagy (H and I) were analyzed in SW1736 and 8505C cells transfected with miR-200a-3p or NC by MTT, flow cytometry, trans-well assay, GFP-LC3 puncta fluorescence assay, or western blot, respectively. *P < .05.

Figure 4. miR-200a-3p was bound to MALAT1. (A) The potential binding sites of miR-200a-3p and MALAT1 were predicted by starBase v2.0. (B and C) The luciferase activity was measured in 8505C cells co-transfected with MALAT1-wt or MALAT1-mut and miR-200a-3p, NC, anti-miR-200a-3p, or anti-NC. (D) The expression of MALAT1 was detected in 8505C cells after Ago2 or IgG RIP assay. (E) The level of MALAT1 was examined in 8505C cells transfected with bio-miR-200a-3p or bio-NC. (F) The abundance of miR-200a-3p was analyzed in 8505C cells transfected with MALAT1, vector, siMALAT1, or scramble. *P < .05.
displayed elevated MALAT1 level (Figure 1A). Similarly, MALAT1 expression was also enhanced in SW1736 and 8505C cells compared with that in Nthy-ori 3-1 cells (Figure 1B). Moreover, by dividing the patients according to the median value of MALAT1 abundance, patients in high MALAT1 expression group showed poor survival compared with those in low expression group, which was statistically significant ($P = .004$) (Figure 1C).

### Knockdown of MALAT1 inhibited ATC cells progression

To investigate the effect of MALAT1 on ATC progression, siMALAT1 or scramble was transfected into SW1736 and 8505C cells. As a result, transfection of siMALAT1 led to an obvious reduction of MALAT1 expression in SW1736 and 8505C cells compared with treatment of scramble (Figure 2A). Moreover, knockdown of MALAT1 significantly inhibited cell
proliferation at different time points in SW1736 and 8505C cells (Figure 2B). However, the apoptotic rate was remarkably increased in SW1736 and 8505C cells transfected with siMALAT1 compared with that in scramble group (Figure 2C).

In addition, abrogation of MALAT1 resulted in great loss of abilities of migration and invasion in SW1736 and 8505C cells (Figure 2D and E). Besides, autophagy formation was analyzed in SW1736 and 8505C cells. Results showed that inhibition of MALAT1 enhanced GFP-LC3 positive signals and promoted the expression of Beclin 1 protein as well as LC3-II/I ratio in SW1736 and 8505C cells (Figure 2F and G).

Overexpression of miR-200a-3p impeded progression of ATC

qRT-PCR assay showed that miR-200a-3p expression was abnormally lowered in ATC tissues or cells compared with that in their corresponding control, respectively (Figure 3A and B). To explore the potential roles of miR-200a-3p in ATC, SW1736 and 8505C cells were transfected with miR-200a-3p or NC. The abundance of miR-200a-3p was effectively elevated in SW1736 and 8505C cells transfected with miR-200a-3p compared with that in NC group (Figure 3C).
MTT analysis displayed that addition of miR-200a-3p limited proliferation of SW1736 and 8505C cells (Figure 3D). Nevertheless, miR-200a-3p had an opposite effect in terms of apoptosis of SW1736 and 8505C cells (Figure 3E). Moreover, accumulation of miR-200a-3p significantly decreased the number of migrated or invasive cells in SW1736 and 8505C cells (Figure 3F and G). The fluorescence assay exhibited more GFP-LC3 puncta in SW1736 and 8505C cells transfected with miR-200a-3p compared with that in NC group (Figure 3H). Besides, overexpression of miR-200a-3p led to an obvious increase of Beclin 1 abundance and ratio of LC3-II/I in SW1736 and 8505C cells (Figure 3I).

**MALAT1 regulated ATC progression by sponging miR-200a-3p**

Seeing the regulatory effect of MALAT1 and miR-200a-3p in ATC, the interaction between MALAT1 and miR-200a-3p was explored in 8505C cells. Bioinformatics analysis provided the putative binding sites of MALAT1 and miR-200a-3p by starBase v2.0, suggesting the potential relationship between MALAT1 and miR-200a-3p (Figure 4A). Subsequently, the prediction was validated by luciferase activity, RIP, and RNA pull-down analyses. Results showed that addition of miR-200a-3p lowered the luciferase activity in 8505C cells transfected with MALAT1-wt, whereas its efficacy was lost in response to MALAT1-mut group (Figure 4B). However, knockdown of miR-200a-3p caused an opposite effect on luciferase activity in 8505C cells (Figure 4C). Moreover, RIP assay showed that enrichment of MALAT1 was obviously enhanced in Ago2 group compared with that in IgG group (Figure 4D). In addition, bio-miR-200a-3p led to higher MALAT1 level than treatment of bio-NC in 8505C cells (Figure 4E). Besides, the expression of miR-200a-3p was measured in 8505C cells transfected with MALAT1, vector, siMALAT1, or scramble. qRT-PCR assay showed that addition of MALAT1 limited the expression of miR-200a-3p while its absence promoted miR-200a-3p abundance in 8505C cells (Figure 4F). To investigate whether miR-200a-3p was required for MALAT1-addressed inhibitory role in progression of ATC, SW1736 and 8505C cells were transfected with scramble, siMALAT1, siMALAT1, and anti-miR-200a-3p or anti-NC. As a result, knockdown of MALAT1 resulted in significantly elevated miR-200a-3p level in SW1736 and 8505C cells, while deficiency of miR-200a-3p attenuated the expression (Figure 5A). Furthermore, down-regulation of miR-200a-3p alleviated the effect of MALAT1 knockdown on proliferation, apoptosis, migration, invasion, and autophagy in SW1736 and 8505C cells (Figure 5B–G).

**miR-200a-3p regulated progression of ATC by targeting FOXA1**

To elucidate the potential mechanism underlies miR-200a-3p-mediated progression in ATC, one promising target of miR-200a-3p was expected to be explored. Bioinformatics analysis displayed the potential binding sites of miR-200a-3p and FOXA1 by TargetScan, indicating the putative interaction between miR-200a-3p and FOXA1 (Figure 6A). Subsequently, the prediction was confirmed by luciferase activity and RIP analyses in 8505C cells. Results showed that overexpression of miR-200a-3p lowered the luciferase activity in 8505C cells transfected with FOXA1-wt, whereas the effect was little with respect to FOXA1-mut group (Figure 6B). Moreover, addition of miR-200a-3p significantly contributed to the enrichment of FOXA1 by Ago2, while IgG failed to show any efficacy for the enrichment in 8505C cells (Figure 6C). Then, the effect of miR-200a-3p on FOXA1 expression was investigated in 8505C cells. Western blot analysis displayed that overexpression of miR-200a-3p suppressed FOXA1 protein level and its knockdown showed an opposite effect (Figure 6D). To explore whether FOXA1 was involved in miR-200a-3p-mediated inhibition of progression of ATC, SW1736 and 8505C cells were transfected with NC, miR-200a-3p, miR-200a-3p, and FOXA1 or empty vector. Furthermore, restoration of FOXA1 attenuated miR-200a-3p-mediated inhibition of proliferation, migration, and invasion and promotion of apoptosis and autophagy in SW1736 and 8505C cells transfected with miR-200a-3p (Figure 6E–J).

**FOXA1 expression was regulated by MALAT1 and miR-200a-3p**

To probe whether MALAT1 functioned as a ceRNA for miR-200a-3p to regulate FOXA1 expression, the relationships among their abundances were analyzed in ATC tissues. Results showed that miR-200a-3p expression was negatively correlated with MALAT1 or FOXA1 level in ATC tissues (Figure 7A and B). Additionally, FOXA1 expression was positively correlated with MALAT1 level in ATC tissues (Figure 7C). Besides, the expression of FOXA1 protein was measured in SW1736 and 8505C cells transfected with siMALAT1, scramble, siMALAT1, and anti-NC or anti-miR-200a-3p. Western blots assays revealed that knockdown of MALAT1 suppressed FOXA1 protein expression, whereas it was ablated by inhibition of miR-200a-3p in SW1736 and 8505C cells (Figure 7D).

**Inhibition of MALAT1 decreased xenograft tumor growth by regulating miR-200a-3p and FOXA1**

To explore the effect of MALAT1 on ATC in vivo, shMALAT1 or scramble-transfected SW1736 or 8505C cells were introduced into nude mice. Knockdown of MALAT1 significantly decreased tumor volume and weight in SW1736 and 8505C xenograft model (Figure 8A and B). Moreover, the expressions of miR-200a-3p and FOXA1 were measured in tumor tissues. Results showed that deficiency of MALAT1 enhanced miR-200a-3p expression in tissues from SW1736 and 8505C xenograft mice (Figure 8C). Besides, FOXA1 protein abundance was obviously decreased in shMALAT1 group compared with that in scramble group in tumor tissues from SW1736 and 8505C xenograft mice (Figure 8D).

**Discussion**

The former finding has revealed that many lncRNAs were ectopic in human thyroid cancer and might be used to improve...
Moreover, various emerging biomarkers are reported to be up-regulated and involved in the pathogenesis of thyroid cancer, including MALAT1. Similarly, we also found that MALAT1 expression was enhanced in ATC tissues and cells, suggesting the potential promoting role of MALAT1. However, little is known about the roles of MALAT1 and mechanism in the progression of ATC. In this study, we first provided the ceRNA regulatory network that was investigated in SW1736 and 8505C cells. *P < .05.

**Figure 7.** FOXA1 expression was regulated by MALAT1 and miR-200a-3p in ATC cells. (A) The relationship between MALAT1 level and miR-200a-3p expression was explored in ATC tissues. (B) The association between FOXA1 mRNA level and miR-200a-3p abundance was measured in ATC tissues. (C) The correlation between FOXA1 mRNA level and MALAT1 expression was analyzed in ATC tissues. (D) The effect of inhibition of MALAT1 or (and) miR-200a-3p on FOXA1 protein expression was investigated in SW1736 and 8505C cells. *P < .05.

**Figure 8.** Deficiency of MALAT1 suppressed tumor growth by regulating miR-200a-3p and FOXA1 protein in xenograft model. (A and B) Tumor volume and weight were measured in SW1736 and 8505C xenograft model. (C) The expression of miR-200a-3p was measured in SW1736 and 8505C xenograft model by qRT-PCR. (D) The abundance of FOXA1 protein was detected in SW1736 and 8505C xenograft model by western blot. *P < .05.
MALAT1 regulated progression of ATC by acting as a ceRNA to sponge miR-200a-3p to mediate FOXA1. MALAT1 has been suggested to be dysregulated in many conditions and participate in multiple cell behaviors, such as proliferation, apoptosis, migration, EMT, autophagy, and differentiation. Notably, MALAT1 was suggested to promote cell proliferation and invasion in thyroid cancer cells by regulating IQ motif containing GTPase activating protein 1 (IQGAP1). Moreover, MALAT1 was indicated to contribute to cell proliferation, migration, invasion, and vasculature formation in thyroid cancer cells via modulating fibroblast growth factor-2 (FGF2). However, the interaction between MALAT1 and autophagy in ATC is still uncertain. Here, we showed that MALAT1 knockdown inhibited cell proliferation, migration, invasion, and promoted cell apoptosis and autophagy in ATC cells, uncovering MALAT1 as an oncogene in ATC, which is also in agreement with previous demonstrations. However, the potential mechanism needs to be further elucidated. Recently, ceRNA hypothesis has shown promise in functional lncRNAs by acting as miRNA sponges to mediate the abundance of miRNA targets in various cancers. Here, we hypothesized that MALAT1 might act as a ceRNA to regulate ATC progression. Accruing literatures have revealed many target miRNAs of MALAT1, such as miR-34a and miR-124. Here, we first identified miR-200a-3p as a target of MALAT1 in ATC cells.

miR-200a-3p has been revealed as a tumor suppressor in many cancers, including renal cell carcinoma and hepatocellular carcinoma. In this study, we revealed that miR-200a-3p expression was impaired in ATC tissues and cells, which is also consistent with previous effort that suggested low expression of miR-200a-3p in thyroid cancer. Mechanistically, we demonstrated that overexpression of miR-200a-3p limited ATC progression. To explore how miR-200a-3p influenced progression of ATC, potential target was predicted by online tool. This study provided FOXA1 as a functional target of miR-200a-3p, which was confirmed by luciferase activity and RIP assays.

The emerging evidence suggested that FOXA1 was differently expressed in various subtypes of thyroid cancers. Moreover, FOXA1 was indicated as an oncogene in ATC to promote cell proliferation and regulate cell cycle. In this study, we found that FOXA1 attenuated miR-200a-3p-mediated inhibitory effect on progression of ATC. This is also indicated the carcinogenic role of FOXA1 in ATC. Moreover, we displayed that FOXA1 was positively regulated by MALAT1 and negatively regulated by miR-200a-3p, reflecting that MALAT1 addressed the ceRNA network to regulate miR-200a-3p and FOXA1 in ATC cells, which was also validated by in vivo experiments. Autophagy may play roles in tumor suppression and progression in different subtypes of thyroid cancers by various pathways. Here, as a biomarker of autophagy, was suggested to have a tumor suppressive function in thyroid cancer. Here, we found that inhibition of MALAT1 induced apoptosis and autophagy in ATC cells. However, the interaction between autophagy and development of ATC and related signaling pathways were absent in this study. Hence, an in-deep study on autophagy in ATC progression is required in future.

In conclusion, MALAT1 was up-regulated in ATC and its knockdown of MALAT1 inhibited cell proliferation, migration, and invasion but increased apoptosis and autophagy formation in ATC cells, which might be associated with miR-200a-3p and FOXA1. This study elucidated the therapeutic effect of MALAT1 silence and the ceRNA network of MALAT1/miR-200a-3p/FOXA1, providing a promising avenue for treatment of ATC.

Disclosure of Potential Conflicts of Interest
The authors declare that they have no financial and non-financial conflicts of interest.

References
1. Siegel RL, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442.
2. Saini S, Tulla K, Maker A, Burman K, Prabhakar B. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17:154. doi:10.1186/s12943-018-0903-0.
3. Tiedje V, Stuschke M, Weber F, Drale H, Moss L, Führer D. Anaplastic thyroid carcinoma: review of treatment protocols. Endoc Relat Cancer. 2018;25:R153–R161. doi:10.1530/ERC-17-0435.
4. Jing W, Li X, Peng R, Lv S, Zhang Y, Cao Z, Tu J, Ming L. The diagnostic and prognostic significance of long noncoding RNAs expression in thyroid cancer: a systematic review and meta-analysis. Pathol Res Pract. 2018;214:327–334. doi:10.1016/j. prp.2018.01.008.
5. Wang XM, Liu Y, Fan YX, Liu Z, Yuan QL, Jia M, Geng ZS, Gu L, Lu XB. LncRNA PTSC3S affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 2018;19:590–597. doi:10.1089/cbz.2018.1449610.
6. Wang Y, Hou Z, Li D. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR-135a-mediated c-myc activation. Mol Med Rep. 2018;18:3068–3076. doi:10.3892/ mmr.2018.9276.
7. Liu K, Huang W, Yan D, Luo Q, Min X. Overexpression of long intergenic noncoding RNA LINC00312 inhibits the invasion and migration of thyroid cancer cells by down-regulating microRNA-197-3p. Biosci Rep. 2017;37:BSR20170109. doi:10.1042/BSR20170109.
8. Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. MALAT1: a long non-coding RNA highly associated with human cancers. Oncol Lett. 2018;16:19–26. doi:10.3892/ol.2018.8613.
9. Amorosi N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018;11:63. doi:10.1186/s13045-018-0606-4.
10. Zhang R, Hardin H, Huang W, Chen J, Ascoli S, Righi A, Maletta F, Sapino A, Lloyd R. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol. 2017;28:7–12. doi:10.1022/2016-9453-4.
11. Liu J, Dong H, Yang Y, Qian Y, Liu J, Li Z, Guan H, Chen Z, Li C, Zhang K, et al. Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value. Future Oncol. 2018;14:3015–3022. doi:10.2217/fon-2018-0416.
12. Chan JJ, Tai Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19:E1310. doi:10.3390/ijms19051310.
13. Peng N, Shi L, Zhang Q, Hu Y, Wang N, Ye H. Microarray profiling of circular RNAs in human papillary thyroid carcinoma. PLoS One. 2017;12:e0170287. doi:10.1371/journal.pone.0170287.
14. Wu D, Wang S, Wen X, Han X, Wang Y, Shen M, Fan S, Zhang Z, Shan Q, Li M, et al. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma. Cell Death Dis. 2018;9:947. doi:10.1038/s41419-018-0975-1.
15. Nonaka D. A study of FoxA1 expression in thyroid tumors. Hum Pathol. 2017;65:217–224. doi:10.1016/j.humpath.2017.05.007.
16. Nucera C, Eckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009;15:3680–3689. doi:10.1158/1078-0432.CCR-08-3155.
17. Murugan AK, Munirajan AK, Alzahrani AS. Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. Endocr Relat Cancer. 2018;25:R59–R82. doi:10.1530/ERC-17-0188.
18. Lei L, Chen J, Huang J, Lu J, Pei S, Ding S, Kang L, Xiao R, Zeng Q. Functions and regulatory mechanisms of metastasis-associated lung adenocarcinoma transcript 1. J Cell Physiol. 2018;234:134–151. doi:10.1002/jcp.26759.
19. Huang JK, Ma L, Song WH, Lu BY, Huang YB, Dong HM, Ma XK, Zhu ZZ, Zhou R. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother. 2016;83:1–7. doi:10.1016/j.biopha.2016.05.039.
20. Huang JK, Song WH, Lu BY, Huang YB, Dong HM, Ma XK, Zhu ZZ, Zhou R. LncRNA-MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGF2 protein secretion. J Cell Biochem. 2017;118:4821–4830. doi:10.1002/jcb.26153.
21. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710–718. doi:10.1136/jmedgenet-2015-103334.
22. Lu M, Xu X, Xi B, Dai Q, Li C, Su L, Zhou X, Tang M, Yao Y, Yang J. Molecular network-based identification of competing endogenous RNAs in thyroid carcinoma. Genes. 2018;9:E44. doi:10.3390 GENES9100044.
23. Duan G, Zhang C, Xu C, Xu C, Zhang L, Zhang Y. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR-34a/cyclin D1 axis. Int J Oncol. 2019;54:17–28. doi:10.3892/ijo.2018.4600.
24. Huang J, Yang Y, Fang F, Liu K. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation. J Cell Biochem. 2018;119:3853–3863. doi:10.1002/jcb.26464.
25. Wang X, Jiang F, Song H, Li X, Xian J, Gu X. MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. Biochem Biophys Res Commun. 2016;470:620–626. doi:10.1016/j.bbrc.2016.01.095.
26. Gong Y, Mao J, Wu D, Wang X, Li L, Zhu L, Song R. Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6. Cancer Cell Int. 2018;18:222. doi:10.1186/s12935-018-0602-3.
27. Kim HM, Kim ES, Koo JS. Expression of autophagy-related proteins in different types of thyroid cancer. Int J Mol Sci. 2017;18: E540. doi:10.3390/ijms18030540.
28. Netea-Maier RT, Viola K, Plantinga TS, Smit JWA. Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol. 2015;6:22. doi:10.3389/fendo.2015.00022.